LMAN2

Across TCGA pan-cancer cohorts, LMAN2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated LMAN2 data layer compared with 27 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher LMAN2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated LMAN2 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

STAD, MESO, and UCEC are the cancer types where LMAN2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Median	III,IV	0.178	0.594	.003	18	view →
MESO	DFS	Median	III,IV	0.078	0.376	.012	9	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	III,IV	0.835	0.489	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

LMAN2–STAD (DFS)

Open the STAD breakdown →